Cargando…

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer

The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menyhárt, Otília, Pongor, Lőrinc Sándor, Győrffy, Balázs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331584/ https://www.ncbi.nlm.nih.gov/pubmed/30670970 http://dx.doi.org/10.3389/fphar.2018.01522

Ejemplares similares

Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes
por: Menyhart, Otília, et al.
Publicado: (2019)

KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer
por: Nagy, Ádám, et al.
Publicado: (2016)

A snapshot of 3649 Web-based services published between 1994 and 2017 shows a decrease in availability after 2 years
por: Ősz, Ágnes, et al.
Publicado: (2017)

Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis
por: Menyhárt, Otília, et al.
Publicado: (2021)

Different mutations in SARS-CoV-2 associate with severe and mild outcome
por: Nagy, Ádám, et al.
Publicado: (2021)

Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan
por: Menyhárt, Otília, et al.
Publicado: (2019)

Principles of tumorigenesis and emerging molecular drivers of SHH‐activated medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches
por: Menyhárt, Otília, et al.
Publicado: (2020)

Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies
por: Menyhárt, Otília, et al.
Publicado: (2021)

The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy
por: Zhu, Chenjing, et al.
Publicado: (2019)

Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030
por: Menyhárt, Otília, et al.
Publicado: (2018)

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
por: Nagy, Ádám, et al.
Publicado: (2018)

Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting
por: Pongor, Lőrinc S., et al.
Publicado: (2020)

Author Correction: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
por: Nagy, Ádám, et al.
Publicado: (2018)

Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma
por: Menyhárt, Otília, et al.
Publicado: (2018)

MultipleTesting.com: A tool for life science researchers for multiple hypothesis testing correction
por: Menyhart, Otília, et al.
Publicado: (2021)

Correction: MultipleTesting.com: A tool for life science researchers for multiple hypothesis testing correction
por: Menyhart, Otília, et al.
Publicado: (2022)

Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer
por: Pálinkás, Hajnalka Laura, et al.
Publicado: (2022)

COVIDOUTCOME—estimating COVID severity based on mutation signatures in the SARS-CoV-2 genome
por: Nagy, Ádám, et al.
Publicado: (2021)

Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation
por: Pongor, Lőrinc, et al.
Publicado: (2017)

A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients
por: Pongor, Lőrinc, et al.
Publicado: (2015)

TP53 mutation hits energy metabolism and increases glycolysis in breast cancer
por: Harami-Papp, Hajnalka, et al.
Publicado: (2016)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

A Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial Results
por: Ligeti, Balázs, et al.
Publicado: (2015)

Fast and Sensitive Alignment of Microbial Whole Genome Sequencing Reads to Large Sequence Datasets on a Desktop PC: Application to Metagenomic Datasets and Pathogen Identification
por: Pongor, Lőrinc S., et al.
Publicado: (2014)

Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
por: Chen, Li, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes
por: Chen, Li, et al.
Publicado: (2022)

Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer
por: Bellanger, Aurélie, et al.
Publicado: (2021)

Jianpi Yangzheng Xiaozheng decoction alleviates gastric cancer progression via suppressing exosomal PD-L1
por: Chen, Yanzhen, et al.
Publicado: (2023)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
por: Zhu, Jiaxin, et al.
Publicado: (2019)

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer
por: Menyhart, Otília, et al.
Publicado: (2017)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1
por: Cimas, Francisco J., et al.
Publicado: (2020)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g86r29769j36432ac2nbj4s8li